merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Safety risks, including significant brain swelling and bleeding, which could potentially outweigh the modest cognitive decline slowdown</answer>

<question_number>2</question_number>
<answer>Might discourage patients from participating in trials for potentially better treatments, potentially slowing progress in Alzheimer's research</answer>

<question_number>3</question_number>
<answer>No correlation between amyloid plaque removal and clinical response in individual subjects</answer>

<question_number>4</question_number>
<answer>Could raise concerns about the drug's safety, as donanemab had higher rates of brain swelling and bleeding compared to Leqembi</answer>

<question_number>5</question_number>
<answer>Patients can potentially stop treatment after amyloid is cleared, which could reduce overall cost and treatment duration</answer>

<question_number>6</question_number>
<answer>Some experts worry that emphasis on anti-amyloid drugs might discourage participation in trials for alternative treatments</answer>

<question_number>7</question_number>
<answer>Patients can stop treatment after amyloid is cleared, potentially reducing treatment frequency and ongoing dosing</answer>

<question_number>8</question_number>
<answer>Amyloid protein</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Patients with intermediate tau levels declined more slowly on donanemab than those with high tau levels</answer>